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LEITER TO THE EDITOR 
POSTIRANSPLANT DIABETES IN PEDIATRIC RECIPIENTS ON TACROLIMUS 
We read with interest the report by Moxey-Mims et aI., 
"Increased Incidence of Insulin-Dependent Diabetes Mellitus 
in Pediatric Renal Transplant Patients Receiving Tacrolimus 
(FK506)," reporting a 100% incidence of posttransplant dia-
betes mellitus in five pediatric patients receiving tacrolimus-
based immunosuppression after renal transplantation (1). 
Although posttransplant diabetes mellitus (PTDM) has been 
a commonly observed complication in adult patients receiv-
ing tacrolimus, with an initial incidence of 6.0-28.3% and a 
final incidence of2.5-12.8% (2-9), it has been less common in 
pediatric patients, and has tended to be reversible in the 
overwhelming majority ofthe cases (10-13). The incidence of 
100% reported by the authors is substantially at variance 
with the incidence that we and others have seen; of perhaps 
greater concern is the seeming lack of reversibility in most of 
the patients, If we are to infer from their article, three of the 
five children are still on insulin. 
Our speculation, to be frank, is that these patients are 
being chronically overimmunosuppressed. Steroid with-
drawal has been possible in some two thirds of pediatric 
recipients (11), and, in patients not withdrawn from steroids, 
relatively low dosages can be achieved relatively soon after 
transplantation. In addition, the target tacrolimus levels de-
scribed by the authors are high, although the actual figures 
described in the patients in question are not excessively out 
of range. 
It has been our experience, and that of others, that PTDM 
is largely reversible with appropriate reduction in the dos-
ages of both tacrolimus and prednisone. It would be interest-
ing to see what would happen to the patients described in 
this article if an attempt was made to decrease the dosages of 
both tacrolimus and steroids. 
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